Empagliflozin in heart failure with a preserved ejection fraction

Autor: Bela Merkely, Nikolaus Marx, Subodh Verma, Michele Senni, Eduardo Chuquiure-Valenzuela, James L. Januzzi, Vijay K. Chopra, Dong-Ju Choi, Stefan D. Anker, Stefano Taddei, Ileana L. Piña, Juan Esteban Gomez-Mesa, Jose R Gonzalez-Juanatey, Dragos Vinereanu, Sergio V. Perrone, Faiez Zannad, Jian Zhang, Carolyn Su Ping Lam, Stuart J. Pocock, Stefan Janssens, Iain Squire, Waheed Jamal, Hans-Peter Brunner-La Rocca, Peter E. Carson, Javed Butler, David K.L. Sim, EMPEROR-Preserved Trial Investigators, Stephen J. Nicholls, Hiroyuki Tsutsui, Janet Schnee, Martina Brueckmann, João Pedro Ferreira, Piotr Ponikowski, Naveed Sattar, Gerasimos Filippatos, Sven Schnaidt, Edimar Bocchi, Michael Böhm, Jindrich Spinar, Cordula Zeller, Nadia Giannetti, Milton Packer

Publikováno v: The New England Journal of Medicine, 385, 16, pp. 1451-1461
New England Journal of Medicine, 385(16), 1451-1461. MASSACHUSETTS MEDICAL SOCIETY
N. Engl. J. Med. 385, 1451-1461 (2021)
The New England Journal of Medicine, 385, 1451-1461

Item does not contain fulltext BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ef0d16771035c4e1ad15d0feed20fd3
http://hdl.handle.net/10281/373399